Claudin 18.2-Targeted Drugs: Regulatory Status and Clinical Development
FDA and EMA Approved Drugs
-
-
ESMO Oncology Updates: What’s New in Cancer Treatment This Week
The latest European Society for Medical Oncology (ESMO) research is reshaping how we treat cancer across multiple tumor types. Here’s a breakdown of the most exciting advances—explained in practical terms for your clinic and patients.
-
2025 updates to TOPAZ-1
Article Details · Title: Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study · Authors: Do-Youn Oh, A.R. He, et al. · Journal: Journal of Hepatology · Publication Date: April 2025 (ePub) · DOI: 10.1016/j.jhep.2025.02.019 (approximate based on recent listing) 5 Key Takeaways · Doubled…
-
EV-302: The Trial That Revolutionized First-Line Bladder Cancer Treatment
EV-302: The Trial That Revolutionized First-Line Bladder Cancer Treatment Article Title: Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer Authors: Thomas Powles, Begona P. Valderrama, Shilpa Gupta, Jens Bedke, Eiji Kikuchi, Jennifer Hoffman-Censits, Gopa Iyer, Christof Vulsteke, Se Hoon Park, Sang Joon Shin, and the EV-302/KEYNOTE-A39 Study Group Journal: New England Journal of…
-
A New Dawn in 2026: Why Your Strength Matters More Than Ever
A New Dawn in 2026: Why Your Strength Matters More Than Ever As we step into 2026, many of us working within the NHS are wrestling with a sobering truth: the challenges feel relentless and the reprieve distant. Staff shortages, overwhelming patient numbers, the gnawing knowledge that we cannot always provide the care…
-
Predicting Treatment Success with Lutetium-177-PSMA: New Nomograms from the VISION Trial
Treatment selection in advanced prostate cancer just got sharper. Lutetium-177-PSMA-617 (Pluvicto®) has changed the landscape for metastatic castration-resistant prostate cancer (mCRPC). But with high costs, potential toxicity, and variable responses, the million-dollar question remains: Who will actually benefit? New data published in eClinicalMedicine (October 2024) gives us the first high-quality, validated nomograms to answer this…
-
MUST READ – Why small things matter : the scientific indisputable proof and why it matters
10 Key Practical Takeaway Points: Applying Chaos Theory to Clinical Practice 1. Accept Uncertainty as Fundamental — Stop viewing unpredictability as a failure of medical knowledge. Uncertainty is inherent in complex adaptive systems, not a deficiency to eliminate. This reframe allows you to practice with authenticity. 2. Small Compassionate Acts Matter Disproportionately — The butterfly…
-
NAPOLI-3 Trial: A Breakthrough in Metastatic Pancreatic Cancer Treatment
Comprehensive review of NAPOLI 3 trials results
-
Weekly Journal Scan : Keep up to date
Latest Updates from Major Medical Journals December 2025 Summary
-
Practice Changing Article review : CheckMate 649 – Five-Year Survival Data Redefines the Standard of Care for Advanced Gastric Cancer
CheckMate 649: Five-Year Survival Data Redefines the Standard of Care for Advanced Gastric Cancer
